Bicara Therapeutics (BCAX) versus Its Peers Financial Analysis

Bicara Therapeutics (NASDAQ:BCAX) is one of 620 public companies in the “MED – BIOMED/GENE” industry, but how does it compare to its peers? We will compare Bicara Therapeutics to similar businesses based on the strength of its analyst recommendations, earnings, institutional ownership, profitability, risk, valuation and dividends.

Valuation & Earnings

This table compares Bicara Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Bicara Therapeutics	N/A	-$68.00 million	-3.79
Bicara Therapeutics Competitors	$884.45 million	-$46.66 million	-0.56

Bicara Therapeutics’ peers have higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Bicara Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-21.67%	-20.89%
Bicara Therapeutics Competitors	-1,418.64%	-631.15%	-29.14%

Institutional & Insider Ownership

51.0% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 15.5% of Bicara Therapeutics shares are owned by insiders. Comparatively, 13.8% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Bicara Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	0	1	8	1	3.00
Bicara Therapeutics Competitors	3624	11410	36029	1004	2.66

Bicara Therapeutics presently has a consensus price target of $32.25, indicating a potential upside of 168.31%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 2,427.82%. Given Bicara Therapeutics’ peers higher probable upside, analysts clearly believe Bicara Therapeutics has less favorable growth aspects than its peers.

Summary

Bicara Therapeutics beats its peers on 7 of the 12 factors compared.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.